We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    2014-A01236-41 | Cystic Fibrosis
Previous Study | Return to List | Next Study

Correction of Nonsense Mutations in Cystic Fibrosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03670472
Recruitment Status : Recruiting
First Posted : September 13, 2018
Last Update Posted : November 18, 2020
Vaincre la Mucoviscidose
Information provided by (Responsible Party):
University Hospital, Lille

Brief Summary:

The presence of a nonsense mutation leads to the rapid degradation of the carrier mRNA mutation by a mechanism called NMD (nonsense-mediated mRNA decay) [6, 13]. There are currently 3 main strategies at least for correcting nonsense mutations: exon skipping, inhibition of NMD and nonsense mutation readthrough.

In the laboratory, we developed a strategy for correcting nonsense mutations combining inhibition of NMD and activation of translecture. For this purpose, we have constructed screening systems to identify NMD-inhibiting and/or readthrough enhancers. The molecules thus identified are then tested on cell lines and in murine models carrying a nonsense mutation.

One of our goals is to select a set of molecules that can correct effectively nonsense mutations. For this we have to test these molecules on a great diversity of nonsense mutations.

This work will:

  • determine if we can correct all the nonsense mutations tested with at least one of our molecules
  • determine what is common within a group of mutations corrected by a given molecule
  • be able to assign the parameters that make one mutation is corrected by one molecule and not or little by another.

This study will therefore improve our theoretical knowledge on the recognition of premature stop codons but also to propose therapeutic approaches for the correction of nonsense mutations of the CFTR gene in cystic fibrosis in a targeted way for a patient.

Condition or disease Intervention/treatment
Cystic Fibrosis Other: smear of nasal fossae

Layout table for study information
Study Type : Observational
Estimated Enrollment : 85 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Optimization of Correcting Molecules of Nonsense Mutations in Epithelial Cells of the Upper Airways of Patients With Cystic Fibrosis With Nonsense Mutations in the CFTR Gene
Actual Study Start Date : February 3, 2016
Estimated Primary Completion Date : January 2030
Estimated Study Completion Date : January 2030

Resource links provided by the National Library of Medicine

Intervention Details:
  • Other: smear of nasal fossae
    1 smear of nasal fossae during a usual or scheduled visit

Primary Outcome Measures :
  1. Transport of iodide ions through the CEVAS membrane [ Time Frame: less than 48hrs after the collect. ]
    Patient cells with be cultured in BEGM (Lonza) medium and incubated with corrector of nonsense mutations for 20 hours and with a fluorescent molecule called SPQ (for 6-methoxy-N-3'-sulfopropylquinolinium). Iodine can bind SPQ and will quench the SPQ fluorescence. Nitrates bind SPQ without quenching SPQ fluorescence. By placing patient cells first into an iodine-rich medium to quench the SPQ fluorescence and second into a nitrate-rich medium, we will be able to measure the level of functional CFTR protein present in these cells by measuring the re-apparition of fluorescence using fluorimeter. Indeed, nitrate will be able to replace iodine on SPQ without quenching SPQ fluorescence only if iodine exits cells through CFTR channels. This assay allows determining whether a corrector of nonsense mutation is able to lead to the synthesis of functional CFTR protein

Secondary Outcome Measures :
  1. Immortalization of patient cells [ Time Frame: an average 12 months ]
    Immortalization of patient cells will be attempted by transfection of construct expressing the origin-of-replication defective SV40 as described in Gruenert et al.,2004

  2. Expression of the CFTR gene at the mRNA and protein level [ Time Frame: less than 1 week. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   8 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with cystic fibrosis and carry a nonsense mutation on the 2 alleles of the gene coding for the CFTR channel.

Inclusion Criteria:

  • Male / female adults and minors aged 8 years and over
  • Patients with cystic fibrosis and carry a nonsense mutation on the 2 alleles of the gene coding for the CFTR channel.
  • Patients whose genotype of patients concerning the CFTR gene is known.
  • Patients with social security
  • Major patients who have given their consent
  • Minor patients with parental authorization

Exclusion Criteria:

  • Patients who have a mutation other than nonsense in the CFTR gene
  • Patients whose CFTR gene was not sequenced on the 2 alleles
  • Patients not wishing to participate in this study or persons not giving or not able to give consent.
  • Pregnant or lactating women
  • Patients under curatorship or guardianship

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03670472

Layout table for location contacts
Contact: Anne Prévotat, MD 03 20 44 59 48 ext +33 anne.prevotat@chru-lille.fr
Contact: Fabrice Lejeune, PhD fabrice.lejeune@inserm.fr

Layout table for location information
Camsp Chu Amiens Recruiting
Amiens, France
Hopital Femme Mere Enfant - Hcl - Bron Recruiting
Bron, France
Hôpital Calmette,CHU Recruiting
Lille, France
Principal Investigator: Anne Prévotat, MD         
Aphm Hopital La Timone - Marseille Recruiting
Marseille, France
Chu Montpellier Recruiting
Montpellier, France
Cmp Enfants Aphp Robert Debre - Paris Recruiting
Paris, France
Hu Paris Centre Site Cochin Aphp - Paris 14 Recruiting
Paris, France
Hopitaux Universitaires de Strasbour Recruiting
Strasbourg, France
Sponsors and Collaborators
University Hospital, Lille
Vaincre la Mucoviscidose
Layout table for investigator information
Principal Investigator: Anne Prévotat, MD University Hospital, Lille
Layout table for additonal information
Responsible Party: University Hospital, Lille
ClinicalTrials.gov Identifier: NCT03670472    
Other Study ID Numbers: 2013_59
2014-A01236-41 ( Other Identifier: ID-RCB number, ANSM )
First Posted: September 13, 2018    Key Record Dates
Last Update Posted: November 18, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Hospital, Lille:
Cystic fibrosis
nonsense mutations
CFTR gene
nasal epithelial cells
nonsense mutation readthrough
Additional relevant MeSH terms:
Layout table for MeSH terms
Cystic Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases